Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US‐licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE‐3 (Recombinant Human INsulin Equivalence‐3) study

To establish the pharmacokinetic (PK) and pharmacodynamic (PD) equivalence of proposed biosimilar insulin 70/30 (Biocon's Insulin‐70/30) and HUMULIN® 70/30 (HUMULIN‐70/30; Eli Lilly and Company, IN).

[1]  Insulin — the new battleground for drug pricing , 2022, Nature biotechnology.

[2]  S. Athalye,et al.  Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin‐R with the US‐licensed Humulin® R formulation in healthy subjects: Results from the RHINE‐1 (Recombinant Human INsulin Equivalence‐1) study , 2021, Diabetes, obesity & metabolism.

[3]  Addressing Insulin Access and Affordability: An Endocrine Society Position Statement. , 2021, The Journal of clinical endocrinology and metabolism.

[4]  T. Tankova,et al.  Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review , 2020, Diabetes Therapy.

[5]  E. Sobngwi,et al.  Expert Opinion: Patient Selection for Premixed Insulin Formulations in Diabetes Care , 2018, Diabetes Therapy.

[6]  I. Hirsch,et al.  Availability and Affordability of Essential Medicines: Implications for Global Diabetes Treatment , 2018, Current Diabetes Reports.

[7]  W. Herman,et al.  Insulin Access and Affordability Working Group: Conclusions and Recommendations , 2018, Diabetes Care.

[8]  Ping Zhang,et al.  Economic Costs of Diabetes in the U.S. in 2017 , 2018, Diabetes Care.

[9]  S. Kalra,et al.  EADSG Guidelines: Insulin Therapy in Diabetes , 2018, Diabetes Therapy.

[10]  L. Heinemann,et al.  How to Assess the Quality of Glucose Clamps? Evaluation of Clamps Performed With ClampArt, a Novel Automated Clamp Device , 2015, Journal of diabetes science and technology.

[11]  Marc Suhrcke,et al.  The Economic Costs of Type 2 Diabetes: A Global Systematic Review , 2015, PharmacoEconomics.

[12]  F. Ampudia-Blasco,et al.  Basal plus basal-bolus approach in type 2 diabetes. , 2011, Diabetes technology & therapeutics.

[13]  D. Bright,et al.  Insulin pens vs. vials and syringes: differences in clinical and economic outcomes. , 2011, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.

[14]  M. Aagren,et al.  Coverage of insulin delivery devices and basal insulin analogs by US managed care organizations , 2011, Journal of medical economics.

[15]  E. T. Wondmagegnehu,et al.  Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes. , 2010, European journal of endocrinology.

[16]  M. Wolzt,et al.  AIR Inhaled Insulin Versus Subcutaneous Insulin , 2008, Diabetes Care.

[17]  Lutz Heinemann,et al.  Measurement of insulin absorption and insulin action. , 2004, Diabetes technology & therapeutics.

[18]  I. Macdonald,et al.  Arterial, arterialized venous, venous and capillary blood glucose measurements in normal man during hyperinsulinaemic euglycaemia and hypoglycaemia , 1992, Diabetologia.

[19]  Erzo F. P. Luttmer,et al.  The Cost of Diabetes , 1989, Diabetic medicine : a journal of the British Diabetic Association.

[20]  D. Owens,et al.  Human Insulin: Clinical Pharmacological Studies in Normal Man , 1986 .

[21]  R. DeFronzo,et al.  Glucose clamp technique: a method for quantifying insulin secretion and resistance. , 1979, The American journal of physiology.

[22]  T. Hayes,et al.  Insulin Cost and Pricing Trends , 2020 .

[23]  COSTS AND RATIONING OF INSULIN AND DIABETES SUPPLIES : FINDINGS FROM THE 2018 T 1 INTERNATIONAL PATIENT SURVEY , 2019 .

[24]  A. K. Alhowaish.  Economic costs of diabetes in Saudi Arabia , 2013, Journal of family & community medicine.